A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.

A. Jo Chien, Andrei Goga, Siti Rahmaputri et al.|Journal of Clinical Oncology|2020

Cited by 19